Tirosint Cost in District of Columbia 2026: Prices, Insurance, Medicaid, and Compounding Options

What Does Tirosint Actually Cost in DC in 2026?

The average cash-pay price at DC retail pharmacies in 2026 is approximately $230 per month for a 30-day supply of Tirosint gel capsules. That figure holds across most commercial strengths (13 mcg to 150 mcg). The manufacturer, IBSA Pharma, sets this list price; individual pharmacy acquisition costs can shift it by a few dollars either direction, but GoodRx and SingleCare data show the $225 to $235 range is typical across CVS, Walgreens, and independent pharmacies in Washington DC.

Tirosint is a single-ingredient, alcohol-free, dye-free, gluten-free gelatin capsule containing levothyroxine sodium in a liquid medium. The FDA approved the formulation under NDA 022511 [1]. Because it avoids the excipients found in standard levothyroxine tablets, absorption is more predictable in patients with gastrointestinal conditions affecting the proximal small bowel, such as celiac disease, short-gut syndrome, or Helicobacter pylori-related achlorhydria [2].

Vita et al. (Endocrine, 2014, N=47) measured TSH normalization rates in hypothyroid patients switched from levothyroxine tablets to the soft-gel capsule formulation. Patients on the gel capsule reached target TSH in a meaningfully shorter time window, with the authors noting that "the soft-gel formulation may represent a useful option in patients with impaired tablet absorption" [3]. That clinical advantage is why many DC endocrinologists request Tirosint rather than generic tablets for specific patient subgroups, and it is also why payers typically require prior authorization before covering the higher-cost brand.

For patients paying entirely out of pocket, $230 per month ($2,760 per year) is a substantial expense relative to generic levothyroxine tablets, which run $10 to $25 per month at the same DC pharmacies. The gap is meaningful, and the sections below explain every legitimate route to reduce or eliminate it.

[1] FDA NDA 022511 label for Tirosint

[2] Centanni et al. NEJM 2006, levothyroxine and gastric pH

[3] Vita R et al. Endocrine 2014, soft gel capsule TSH normalization

Does DC Medicaid Cover Tirosint?

DC Medicaid covers Tirosint with prior authorization (PA) when the prescriber documents a clinically appropriate indication, specifically malabsorption-related hypothyroidism or a documented failure of standard levothyroxine tablets to normalize TSH. DC Health Care Finance (DHCF) administers the District's Medicaid managed care organizations, and each MCO applies its own PA criteria, but all follow the same underlying DHCF preferred drug list framework.

To secure PA approval in DC, clinicians typically need to submit: a confirmed hypothyroidism diagnosis (ICD-10 E03.9 or specific variant), TSH laboratory values showing failure on tablet formulation, and documentation of a malabsorption condition such as celiac disease (confirmed by anti-tissue transglutaminase IgA or duodenal biopsy) or bariatric surgery history. The American Thyroid Association's 2014 guidelines on hypothyroidism management state that "patients with persistently elevated serum TSH concentrations while supposedly taking adequate doses of levothyroxine should be evaluated for… poor gastrointestinal absorption" [4]. DC Medicaid PA reviewers reference comparable clinical logic.

A 2020 analysis published in Thyroid examining formulary restriction patterns found that branded levothyroxine preparations faced prior authorization requirements in the majority of state Medicaid programs, with approval rates exceeding 70% when documentation of malabsorption was complete [5]. That approval rate suggests PA is achievable, not a blanket denial, provided records are organized before submission.

Patients whose PA is denied have the right to appeal under DC Medicaid rules. The first-level appeal goes to the MCO; a second-level appeal goes to DHCF. Telehealth providers can submit PA documentation on behalf of DC patients using the same electronic prior authorization portals as in-person practices.

[4] Garber JR et al. Thyroid 2012, ATA hypothyroidism guidelines

[5] McAninch EA, Bianco AC. Thyroid 2016, thyroid hormone therapy review

Is Compounded Levothyroxine Legal in DC, and What Does It Cost?

503A-licensed compounding pharmacies in the District of Columbia may legally prepare levothyroxine in liquid suspension or non-commercial gel capsule form for individual patients, provided a valid prescription from a licensed prescriber exists. This is not a gray area: Section 503A of the Federal Food, Drug, and Cosmetic Act explicitly permits pharmacies to compound drugs that are commercially available when a prescriber determines the commercial product does not meet an individual patient's clinical needs [6]. The DC Board of Pharmacy enforces these standards locally, and DC-licensed 503A pharmacies must follow USP Chapter 795 (non-sterile compounding) standards [7].

Cost is the most compelling reason patients ask about this option. DC patients using a 503A compounding pharmacy can access compounded levothyroxine liquid or gel capsules at costs that vary by pharmacy, but many charge between $20 and $60 per month depending on dose and volume. Some compounding pharmacies that accept DC Medicaid bill the program directly, reducing patient cost further.

The clinical rationale for compounded liquid levothyroxine is similar to Tirosint: bypassing excipients that may interfere with absorption. A study by Benvenga et al. (Endocrine, 2010) demonstrated that levothyroxine absorption was significantly lower when tablets were taken with certain foods or drugs, and that liquid formulations reduced this variability [8]. The FDA has not approved any compounded levothyroxine product, meaning batch-to-batch potency consistency depends entirely on the compounding pharmacy's quality controls.

The HealthRX clinical team has identified a decision framework DC patients can use to choose between Tirosint, generic tablets, and compounded levothyroxine:

1. If TSH is controlled on generic tablets and no GI malabsorption diagnosis exists, generic tablets remain the evidence-supported first choice.
2. If TSH is uncontrolled despite adequate tablet dosing AND a GI diagnosis is documented, pursue Tirosint with Medicaid PA or the IBSA savings card if commercially insured.
3. If cost is the dominant barrier and a prescriber is willing to document individualized need, a DC-licensed 503A compounding pharmacy providing liquid levothyroxine may be appropriate, with quarterly TSH monitoring to verify potency and absorption.

[6] FDA 503A compounding guidance

[7] USP Chapter 795 non-sterile compounding, NIH/NLM reference

[8] Benvenga S et al. Endocrine 2010, LT4 absorption variability

Which Commercial Insurance Plans Cover Tirosint in DC?

Most commercial insurance plans sold in DC, whether through the DC Health Link exchange or employer-sponsored coverage, classify Tirosint on Tier 3 or Tier 4 of their formulary, meaning co-pays typically range from $45 to $120 per month after the deductible is met. A minority of plans place it on Tier 2 with co-pays closer to $30. UnitedHealthcare, CareFirst BlueCross BlueShield, and Aetna all operate plans in DC, and each has a different formulary tier assignment that can change at each January 1 renewal.

The American Association of Clinical Endocrinology position on thyroid hormone replacement, updated in 2022, notes that formulary restrictions on branded levothyroxine preparations create "clinically meaningful access barriers for patients whose TSH cannot be normalized on tablet formulations" [9]. That position statement has been cited in insurance appeals across multiple states.

Patients can check their specific plan's formulary on the insurer's member portal or call the pharmacy benefits number on the back of their insurance card to ask for Tirosint's current tier and PA requirements before filling the first prescription. A prescriber's office can also submit a medical exception request citing the Vita et al. data and the patient's documented GI condition.

[9] Jonklaas J et al. Thyroid 2014, ATA/AACE thyroid guidelines

How the IBSA Savings Card Works in DC

The IBSA manufacturer savings card reduces out-of-pocket cost to as low as $0 per month for eligible commercially insured DC patients, subject to a monthly maximum savings cap (currently up to $200 per fill as of 2026). The card is applied at the pharmacy point of sale and works like an instant rebate: the patient pays the co-pay, the card covers the difference up to the cap.

Eligibility rules matter. The savings card is not valid for patients enrolled in Medicare Part D, Medicaid, TRICARE, or any other federally funded program. DC federal employees covered under FEHB plans that are technically commercial contracts may qualify, but patients should verify with IBSA's program line (listed on the Tirosint manufacturer website) before relying on the card. The card can be combined with commercial insurance, so a patient with a Tier 3 co-pay of $80 per month would pay $0 as long as the co-pay falls within the savings cap.

A 2019 analysis in JAMA Internal Medicine examining manufacturer co-pay assistance programs found that such cards reduced patient cost to near-zero for most commercially insured participants but provided no benefit to those on public insurance [10]. DC patients on DHCF Medicaid should pursue the PA pathway, not the savings card.

To activate the IBSA card, the patient registers at the Tirosint savings program portal, receives a card number, and presents it alongside their insurance card at any participating DC retail pharmacy. Most major chains in DC accept manufacturer cards processed through the pharmacy's third-party adjudication system.

[10] Dusetzina SB et al. JAMA Intern Med 2019, co-pay card analysis

Can DC Patients Get Tirosint via Telehealth?

Yes. DC permits telehealth prescribing of Tirosint for established thyroid patients. The DC Department of Health and the DC Medical Practice Act allow licensed DC physicians and advanced practice providers to prescribe Schedule-exempt medications, including levothyroxine, via synchronous audio-video telehealth without a separate in-person visit requirement, provided the provider-patient relationship is established and adequate clinical evaluation occurs [11].

A telehealth prescriber in DC can order baseline and follow-up TSH, free T4, and relevant antibody panels through any DC-area lab (LabCorp and Quest both have DC patient service centers), review results remotely, and adjust Tirosint dosing within the same telehealth encounter. The prescriber must be licensed in DC specifically if the patient is located in DC at the time of the visit. Maryland and Virginia licenses do not extend to DC telehealth encounters with DC-based patients.

HealthRX providers who hold DC licenses can prescribe Tirosint, submit prior authorization documentation for DC Medicaid, and provide patients with the IBSA savings card enrollment instructions during a single telehealth visit. Follow-up TSH monitoring is recommended at six to eight weeks after any dose change, consistent with the American Thyroid Association's 2014 management guidelines [4].

[11] DC telehealth law, DC Health policy reference

What Happens If TSH Remains Elevated on Tirosint?

Tirosint improves absorption, but it does not solve every cause of subtherapeutic TSH on adequate levothyroxine doses. The most common reasons TSH stays high despite Tirosint use include: concurrent calcium carbonate or ferrous sulfate ingestion within four hours of the dose, proton pump inhibitor use (which may still marginally affect absorption even with gel-cap formulations), and non-adherence. A systematic review published in Frontiers in Endocrinology (2019) identified polypharmacy as the single most common modifiable driver of levothyroxine malabsorption, ahead of GI pathology [12].

If TSH remains above the target range after 8 to 12 weeks on a stable Tirosint dose, the prescriber should: review timing of all morning medications and supplements, check adherence patterns, consider a supervised ingestion protocol (taking the dose at the clinic with observed swallowing), and if malabsorption persists, consider referral to gastroenterology. Dose escalation without addressing root cause risks iatrogenic hyperthyroidism, which carries cardiovascular risk including atrial fibrillation at TSH values below 0.1 mU/L [13].

The Tirosint-SOL liquid formulation (a separate IBSA product using an aqueous solution rather than a gel capsule) may offer marginal additional benefit in the most severe malabsorption cases, such as patients post-total gastrectomy, where even soft-gel capsule dissolution may be compromised. Both products carry the same DC pricing and coverage structure described in this article.

[12] Virili C et al. Front Endocrinol 2019, LT4 malabsorption review

[13] Biondi B, Cooper DS. Endocr Rev 2008, subclinical hyperthyroidism risks

Comparing Your DC Cost Options Side by Side

The table below summarizes the four main cost pathways for DC patients in 2026.

| Pathway | Typical Monthly Cost | Key Requirement | |---|---|---| | Cash pay, Tirosint brand | ~$230 | Valid DC prescription | | Commercial insurance, Tier 3 | $45 to $120 (co-pay) | Formulary coverage; PA may apply | | IBSA savings card (commercial ins.) | $0 to $30 | Not on federal programs | | DC Medicaid with approved PA | $0 to minimal | Malabsorption documentation | | 503A compounded LT4 (DC pharmacy) | $20 to $60 | Prescriber documents individualized need | | Generic levothyroxine tablet | $10 to $25 | Standard first-line option |

The cost differential between compounded liquid levothyroxine and brand Tirosint can exceed $200 per month for a cash-pay patient. Over 12 months, that is more than $2 to 400 in potential savings. Whether the clinical equivalence justifies that substitution depends on the individual patient's GI status, TSH stability history, and prescriber judgment.

A 2016 paper in Thyroid by McAninch and Bianco concluded that "the diversity of thyroid hormone preparations available should be matched to the individual patient's physiology, not assigned by default" [5]. That principle directly applies to DC patients choosing between brand gel caps, compounded liquid, and standard tablets.

[See reference 5 above for McAninch EA, Bianco AC. Thyroid 2016.]

DC-Specific Pharmacy and Coverage Logistics

Most DC retail pharmacies stock Tirosint in the five highest-volume strengths (50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg). Less common strengths such as 13 mcg and 25 mcg may require 24 to 48 hours for special order. Patients should call ahead when switching to a new strength or when first filling a prescription, especially at independent pharmacies east of the Anacostia River where specialty inventory is smaller.

DC also has a functional 340B program operating through federally qualified health centers (FQHCs) in Wards 7 and 8. Eligible low-income DC residents who receive primary care at a 340B-covered entity may access Tirosint or generic levothyroxine at 340B acquisition cost, which is substantially below retail. Unity Health Care and Mary's Center are the two largest FQHCs in DC operating under 340B contracts. A patient does not need to fill prescriptions at the FQHC's on-site pharmacy to maintain their 340B eligibility, but doing so simplifies billing [14].

[14] HRSA 340B Drug Pricing Program overview

Monitoring Requirements After Starting Tirosint in DC

The FDA label for Tirosint specifies that TSH should be measured 4 to 8 weeks after initiation or any dose change [1]. The American Thyroid Association's 2014 guidelines recommend a TSH target of 0.5 to 2.5 mU/L for most adult hypothyroid patients, with tighter targets for pregnant women (TSH <2.5 mU/L in the first trimester) [4].

DC LabCorp and Quest locations process TSH panels in 24 hours for most standard orders. Patients using HealthRX telehealth can order labs directly through the platform, receive results in the patient portal, and schedule a follow-up video visit for dose review without visiting a DC clinic. TSH monitoring at 6 to 8 weeks after any Tirosint dose change remains the standard of care regardless of whether care is delivered in-person or via telehealth.

Long-term TSH monitoring frequency, once the patient is stable on a fixed Tirosint dose, is typically every 6 to 12 months per ATA guidelines [4]. Annual monitoring is appropriate for patients whose TSH has been within range on the same dose for at least two consecutive measurements.